Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Wavefront-guided femto-LASIK efficacy for myopic adult patients with refractive amblyopia

Poster Details

First Author: D.Abelski BELARUS

Co Author(s):    A. Haddad              

Abstract Details



Purpose:

To find out whether wavefront-guided femto-LASIK can improve the postoperative uncorrected visual acuity (UCVA) in comparison with preoperative best spectacle corrected visual acuity (BSCVA) in the group of adult refractive amblyopes.

Setting:

Republican Ophthalmological Center, Minsk, Belarus.

Methods:

Seventeen eyes of 10 consecutive patients (7 isometropic and 3 anisometropic refractive amblyopes without strabismus) underwent wavefront-guided LASIK procedure on WaveScan WaveFront™ System / STAR S4 IR™ eximer laser platform (AMO, Santa Clara, CA, USA). Flap creation was performed on IntraLase™ FS60 femtosecond laser. The efficacy was defined as the positive difference between 3 month post-op UCVA and preoperative BSCVA (both measured in decimal system), 3 month post-op BSCVA was also measured. Mean spherical equivalent refraction (MRSE) in the group was -5.17 +/- 2.42. Target refraction in all cases was emmetropic. Mean pre-op BSCVA was 0.55 +/- 0.25.

Results:

In 9 cases we observed the improvement in post-op UCVA in comparison with preoperative BSCVA, in 5 cases there were no significant difference between two values and in 2 cases we’ve registered the deterioration of post-op UCVA in comparison with preoperative BSCVA (caused by the undercorrection, post-op BSCVA in both cases resembled pre-op BSCVA). Three month postoperative MRSE was -0.1 +/-0.6 and mean UCVA 0.62 +/- 0.22, mean BSCVA was 0.67 +/- 0.27.

Conclusions:

Wavefront guided femto-LASIK is a predictable and effective way of correcting myopia in adult amblyopic patients and is able to improve postoperative UCVA and BSCVA in comparison with preoperative BSCVA. NO financial disclosure.

Financial Disclosure:

NONE

Back to previous